RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Caratterizzazione di molecole microbiche coinvolte con meccanismi di immunità innata
• 2 - Interazioni batterio-cellula ospite: analisi genetica e molecolare di meccanismi di virulenza di patogeni enterici di rilevanza clinica con particolare riferimento alla loro capacità di alterare a proprio vantaggio la risposta immune innata dell’ospite.
• 3 - Legionella pneumophila come patogeno emergente in Sanità Pubblica: nuove prospettive per la valutazione del rischio e strategie innovative per la prevenzione e il controllo della contaminazione ambientale
• 4 - Nuove prospettive sull'immunità innata e l'immunoterapia.
• 5 - Basi genetiche e molecolari della patogenicità batterica
• 6 - Studio della virulenza di batteri intracellulari: aspetti molecolari ed immunologici.
• 7 - PATOGENESI E TERAPIA DELLE MALATTIE DA INFEZIONE
• 8 - Peptidi antimicrobici naturali come composti guida per lo sviluppo di nuovi agenti antinfettivi e per l'identificazione di bersagli batterici adatti alla progettazione di antibiotici innovativi
• 9 - Biofilm microbici come sistema dinamico in risposta allo stress ambientale. Approcci innovativi nella prevenzione e formulazione di nuove strategie terapeutiche integrate.
• 10 - Terapia molecolare dei sarcomi

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • MICROBIOLOGIA E MICROBIOLOGIA CLINICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Toscana

Bibliografia

1. Berrouane Y.F. et al.: Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. Journal of Clinical Microbiology 37, 531-7, 1999
2. Blasi E. et al.: Nramp1 gene affects selective early steps in macrophage-mediated anti-cryptococcal defences. Med. Microbiol. & Immunol. 189: 209-216, 2001
3. Blasi E. et al.: Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus. Nature 318: 667-670, 1985
4. Blasi E. et al.: Biological importance of the two Toll-like receptors, TLR2 and TLR4, in macrophage response to infection with Candida albicans FEMS Immunol. Med. Microbiol. 44: 69-79, 2005
5. Bocchini V. et al.: An immortalized cell line expresses properties of activated microbial cells. J. Neurosci. Res. 31: 616-621, 1992
6. Bougnoux M-E. et al.: Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J. Clin. Microbiol. 41: 5265-66, 2003
7. Calderone R.A. and Fonzi W.A.: Virulence factors of Candida albicans. Trends Microbiol 9: 327-35, 2001
8. Cenci E. et al.: A synthetic peptide as a novel anticryptococcal agent. Cel. Microbiol. 6:953-961, 2004
9. Conti S. et al.: In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant Gram-positive cocci. Molec. Med. 6/7:613-619, 2000
10. Denning D.W.: Echinocandin antifungal drugs. Lancet, 362: 1142-1151, 2003
11. Feldmesser M. et al.: Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68, 4225-4237, 2000
12. Franzot S.P. et al.: Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66: 89-97, 1998
13. Ghannoum M. A et al.: Reduced virulence of Candida albicans PHR1 mutants,Infect. Immun. 63: 4528-30, 1995
14. Gow N.A. et al.: Fungal morphogenesis and host invasion. Curr. Opin. Microbiol.5: 366-71, 2002
15. Hope W. et al.: Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J. Hosp. Infect. 50, 56-65, 2002
16. Hube B.: From commensal to pathogen: stage- and tissue-specific gene expression of Candida albicans. Curr. Opin. Microbiol. 7: 336-41, 2004
17. Hube B., and Naglik J.: Candida albicans proteinases: resolving the mystery of a gene family. Microbiol. 147:1997-05, 2001
18. Káposzta R. et al.: Rapid recruitment of late endosomes and lysosomes in mouse macrophages ingesting Candida albicans. J Cell Sci 112: 3237-3248, 1999
19. Lorenz et al.: Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryotic Cell 3: 1076-87, 2004
20. Lupetti A. et al.: Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Exp. Opin. Investig. Drugs 11: 309-18, 2002
21. Lupetti A. et al.: Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob. Agents Chemother. 44: 3257-63, 2000
22. Lupetti A. et al: Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J. Clin. Microbiol. 40: 2363-69, 2002
23. Lupetti A. et al.: Release of calcium from intracellular stores and subsequent uptake by mitochondria are essential for the candidacidal activity of an N-terminal peptide of human lactoferrin. J. Antimicrob. Chemother. 54: 603-08, 2004
24. Lupetti A. et al: Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob. Agents Chemother. 47: 262-67, 2003.
25. Maresca B. et al.: Molecular approaches to identify novel targets for future development of antifungal agents, J. Med. Vet. Mycol. 32: 287-98, 1994
26. McNeil M.M. et al.: Trends in mortality due to invasive mycotic diseases in the United States,1980-1997. Clin. Infect. Dis. 33, 641.7, 2001.
27. Moragues M.D. et al.: A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun.71:5273-5279, 2003
28. Mouyna I. et al.: Glycosylphosphatidylinositol-anchored glucanosyltransferases play an active role in the biosynthesis of the fungal cell wall, J. Biol. Chem. 275, 14882-9, 2000
29. Odds F. C.: Candida and candidosis: a review and bibliography. 2nd ed. Baillière-Tindall, London, United Kingdom, 1988
30. Odds F.C. et al.: Antifungal agents: mechanism of action. Trends in Microbiology 11, 272-9, 2003
31. Pfaller M. A. et al.: Bloodstream infection due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44:747-51, 2000
32. Polak A.: The past, present and future of antimycotic combination therapy. Mycoses 42: 355-70, 1999
33. Polonelli L. et al.: Human natural yeast killer toxin-like candidacidal antibodies. J. Immunol. 156:1880-1885, 1996
34. Puliti M. et al.: Differential effector and secretory functions of microglial cell lines derived from BCG-resistant and –susceptible congenic mouse strains. J. Neuroimmunol. 101: 27-33, 1999
35. Rangel-Frausto M. S. et al.: National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin. Infect. Dis. 29: 253-58, 1999
36. Romani L. et al.: Adaptation of Candida albicans to the host environment: the role of morphogenesis in virulence and survival in mammalian hosts Curr. Opin. Microbiol. 6: 338-43, 2003
37. Saporito-Irwin S. et al.: PHR1, a pH-regulated gene of Candida albicans, is required for morphogenesis, Mol Cell Biol. 15, 601-13, 1995
38. Searle S.et al.: Localisation of Nramp1 in macrophages: modulation with activation and infection J. Cell. Sci. 111: 2855-2866, 1998
39. Slaven J.W. et al.: Increased expression of a novel Aspergillus fumigatus ABC transporter gene, artF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol., 36: 199-206, 2002
40. Soll D.R.: The ins and outs of DNA fingerprinting the infectious fungi. Clin. Microbiol. Rev. 13: 332-70, 2000
41. Soll D.R.: Candida commensalism and virulence: the evolution of phenotypic plasticity. Acta Trop. 81:101-10, 2002
42. Takeda K. et al.: Roles of Toll-like receptors in innate immune responses. Genes to Cell 6: 733-742, 2001
43. Tavanti A. et al.: Candida albicans isolates with a defined karyotype arecharacterized by resistance to intracellular killing and by the ability to produce hyphae upon internalization by macrophages. J. Clin. Microbiol. , inviato per pubblicazione, 2005
44. Tavanti A. et al.: Candida orthopsilosis and Candida metapsilosis, spp. nov., to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43: 284-92, 2005
45. Tavanti A. et al.: Differential Expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes. J. Clin. Microbiol. 42: 4726-34, 2004
46. Tavanti A. et al.: Molecular monitoring of Candida albicans infections in liver transplant recipients. Europ. J. Clin. Microbiol. Infect. Dis. 20: 544-53, 2001
47. Tavanti A. et al.: Optimization and validation of multi-locus sequence typing for Candida albicans. J. Clin. Microbiol. 41:3756-76, 2003
48. Tortorano A.M. et al.: The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J. of Antimicrob. Chemother. 52, 679-82, 2003
49. Travassos L.R. et al.: Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J.Antimicrob. Chemother. 54:956-958, 2004
50. Vásquez-Torres A., and E. Balish.: Macrophages in resistance to Candidiasis. Microbiol. . Mol. Biol.rev. 61:170-192, 1997
51. Weig M. et al.: A GAS-like gene family in the pathogenic fungus Candida glabrata, Microbiology. 147, 2007-19, 2001

Parole Chiave

FUNGHI PATOGENI OPPORTUNISTI; FATTORI DI VIRULENZA; INFEZIONE MACROFAGICA; INFEZIONE SPERIMENTALE; DIAGNOSI MOLECOLARE; TIPIZZAZIONE GENOTIPICA; NUOVI AGENTI ANTIFUNGINI; PEPTIDI ANTIMICOTICI; INIBITORI DI GAS1/PHR1